BIOMARIN PHARMACEUTICAL INC
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
BMRN$57.13-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
(In thousands of U.S. Dollars)
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| NET INCOME (LOSS) | $167,645 | $141,561 | $(64,080) |
| OTHER COMPREHENSIVE INCOME (LOSS): | |||
| Available-for-sale debt securities: | |||
| Unrealized holding gain (loss) arising during the period, net of tax impact of $(3,922), $3,247 and $1,596, respectively | 12,963 | (10,720) | (5,262) |
| Cash flow hedges: | |||
| Unrealized holding gain (loss) arising during the period, net of tax impact of $0 for all periods presented | (37,720) | 29,045 | 34,379 |
| Less: reclassifications to net income (loss), net of tax impact of $0 for all periods presented | 164 | 36,624 | (1,454) |
| Net change in unrealized holding gain (loss), net of tax | (37,884) | (7,579) | 35,833 |
| OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX | (24,921) | (18,299) | 30,571 |
| COMPREHENSIVE INCOME (LOSS) | $142,724 | $123,262 | $(33,509) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.